| |
|
|
| |
Extended Release CNS Therapeutics
Drugs, Indications, Markets and Prospects
|
Publication: August 2011
Product Code: ERCN227F
|
In terms of dosing regimens and patient compliance,
neurological disorders represent one of the most challenging
areas of therapeutic medicine. Patients diagnosed with
conditions such as schizophrenia, Alzheimer’s disease,
Parkinson’s disease, and manic depressive disorder are often
not physically and/or mentally capable of reliably following
dosing instructions for the medications that they’ve been
prescribed. The availability of approved drugs for
neurological disorders with extended release profiles
creates the potential to improve patient compliance by
extending the time between dosing intervals. Drugs that have
been formulated as extended release versions include a
number of well-known APIs that have traditionally been
marketed as immediate release products. Currently approved
CNS drugs include extended release formulations for a dozen
separate neurological indications. While the majority of
these drugs are oral (tablets or capsules) formulations, the
number of extended release injectable and transdermal drugs
for CNS conditions is increasing.
|
|
Highlights |
· Analyzes and evaluates
CNS drugs formulated for extended release and assesses
the market potential for existing and potential
future products
· Analyzes product
technologies and product development factors
· Provides
detailed assessments of key CNS market segments, market
demographics and business strategies
· Provides market data
and forecasts to 2015
· Profiles market sector
participant companies, their product development
activities and strategies
|
|
Summary of Contents |
Executive Summary
CNS Therapeutics -
Market Dynamics
The Shifting CNS Prescription
Drug Landscape
Unmet Needs in CNS Clinical
Treatment
CNS Therapeutic Demand Drivers
Demographic Shifts
Evolving Drug
Formulation Technology
Growth in Home
Healthcare
Extended Release Technologies and
Product Segments
Oral
Aperture
Systems
Bead Systems
Bi-layer
Tablets
Degradable Polymeric Matrix
Gel Forming Tablets & Capsules
Membrane
Systems
Osmotic Systems
Injectable
Diffusion
Microsphere
Encapsulation
Prodrugs
Transdermal
Matrix
Drug-in-Adhesive
Approved
Extended Release CNS Products
Antidepressants
Antiepileptics
Antipsychotics
Benzodiazepines
CNS Stimulants
Cholinesterase
Inhibitors
Dopamine Agonists
Hypnotics
Psychotropic Drugs
Market Factors
Regulations
Managed Care and Healthcare Economics
Alliances and Private Labeling
CNS
Therapeutics - Extended Release Segment Analysis
ADHD
Alzheimer’s
Depression
Epilepsy
Insomnia
Manic Depressive Disorder
Panic
Disorder
Parkinson’s
Schizophrenia
Seizures
Sector Participant Company Profiles
|
|
|
|
|
